Subtyping of cardiac amyloidosis by mass spectrometry-based proteomics of endomyocardial biopsies

References

• Pepys MB. Amyloidosis. Annu Rev Med. 2006;57:223–241.
   PubMed Web of Science ®Google Scholar
• Benson MD, Buxbaum JN, Eisenberg DS, et al. Amyloid nomenclature 2020: update and recommendations by the international society of amyloidosis (ISA) nomenclature committee. Amyloid. 2020;27(4):217–222.
   PubMed Web of Science ®Google Scholar
• Westermark GT, Westermark P. Islet amyloid polypeptide and diabetes. Curr Protein Pept Sci. 2013;14(4):330–337.
   PubMed Web of Science ®Google Scholar
• Noborn F, Ancsin JB, Ubhayasekera W, et al. Heparan sulfate dissociates serum amyloid A (SAA) from acute-phase high-density lipoprotein, promoting SAA aggregation. J Biol Chem. 2012;287(30):25669–25677.
   PubMed Web of Science ®Google Scholar
• Donnelly JP, Hanna M. Cardiac amyloidosis: an update on diagnosis and treatment. Cleve Clin J Med. 2017;84(12 Suppl 3):12–26.
   PubMed Web of Science ®Google Scholar
• Falk RH, Alexander KM, Liao R, et al. AL (Light-Chain) cardiac amyloidosis: a review of diagnosis and therapy. J Am Coll Cardiol. 2016;68(12):1323–1341.
   PubMed Web of Science ®Google Scholar
• Bezerra F, Saraiva MJ, Almeida MR. Modulation of the mechanisms driving transthyretin amyloidosis. Front Mol Neurosci. 2020;13:592644.
   PubMed Web of Science ®Google Scholar
• Zhao L, Buxbaum JN, Reixach N. Age-related oxidative modifications of transthyretin modulate its amyloidogenicity. Biochemistry. 2013;52(11):1913–1926.
   PubMed Web of Science ®Google Scholar
• Noborn F, O'Callaghan P, Hermansson E, et al. Heparan sulfate/heparin promotes transthyretin fibrillization through selective binding to a basic motif in the protein. Proc Natl Acad Sci USA. 2011;108(14):5584–5589.
   PubMed Web of Science ®Google Scholar
• Dogan A. Amyloidosis: insights from proteomics. Annu Rev Pathol. 2017;12:277–304.
   PubMed Web of Science ®Google Scholar
• Macedo AVS, Schwartzmann PV, de Gusmao BM, et al. Advances in the treatment of cardiac amyloidosis. Curr Treat Options Oncol. 2020;21(5):36.
   PubMed Web of Science ®Google Scholar
• Chandrashekar P, Desai AK, Trachtenberg BH. Targeted treatments of AL and ATTR amyloidosis. Heart Fail Rev. 2022;27(5):1587–1603.
   PubMed Web of Science ®Google Scholar
• Solomon A, Murphy CL, Westermark P. Unreliability of immunohistochemistry for typing amyloid deposits. Arch Pathol Lab Med. 2008;132(1):14; author reply 14–14; author reply 15. author reply 14–5.
   PubMed Web of Science ®Google Scholar
• Vrana JA, Gamez JD, Madden BJ, et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009;114(24):4957–4959.
   PubMed Web of Science ®Google Scholar
• Brambilla F, Lavatelli F, Di Silvestre D, et al. Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood. 2012;119(8):1844–1847.
   PubMed Web of Science ®Google Scholar
• Canetti D, Rendell NB, Gilbertson JA, et al. Diagnostic amyloid proteomics: experience of the UK national amyloidosis Centre. Clin Chem Lab Med. 2020;58(6):948–957.
   PubMed Web of Science ®Google Scholar
• Dasari S, Theis JD, Vrana JA, et al. Amyloid typing by mass spectrometry in clinical practice: a comprehensive review of 16,175 samples. Mayo Clin Proc. 2020;95(9):1852–1864.
   PubMed Web of Science ®Google Scholar
• Alkhawam H, Patel D, Nguyen J, et al. Cardiac amyloidosis: pathogenesis, clinical context, diagnosis and management options. Acta Cardiol. 2017;72(4):380–389.
   PubMed Web of Science ®Google Scholar
• Cappelli F, Gallini C, Di Mario C, et al. Accuracy of 99mTc-hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis. J Nucl Cardiol. 2019;26(2):497–504.
   PubMed Web of Science ®Google Scholar
• Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis. A position statement of the european society of cardiology working group on myocardial and pericardial diseases. Eur J Heart Fail. 2021;23(4):512–526.
   PubMed Web of Science ®Google Scholar
• Seferovic PM, Tsutsui H, McNamara DM, et al. Heart failure association of the ESC, heart failure society of america and japanese heart failure society position statement on endomyocardial biopsy. Eur J Heart Fail. 2021;23(6):854–871.
   PubMed Web of Science ®Google Scholar
• Wiśniewski JR, Zougman A, Nagaraj N, et al. Universal sample preparation method for proteome analysis. Nat Methods. 2009;6(5):359–362.
   PubMed Web of Science ®Google Scholar
• Vrana JA, Theis JD, Dasari S, et al. Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics. Haematologica. 2014;99(7):1239–1247.
   PubMed Web of Science ®Google Scholar
• Gilbertson JA, Gillmore JD, Hawkins PN. Amyloid typing: experience from a large referral Centre. In: Picken M, Herrera G, Dogan A, editors. Amyloid and related disorders. Current clinical pathology. Cham: Humana Press; 2015. p. 273–282.
   Google Scholar
• Lavatelli F, Merlini G. Advances in proteomic study of cardiac amyloidosis: progress and potential. Expert Rev Proteomics. 2016;13(11):1017–1027.
   PubMed Web of Science ®Google Scholar
• Maleszewski JJ. Cardiac amyloidosis: pathology, nomenclature, and typing. Cardiovasc Pathol. 2015;24(6):343–350.
   PubMed Web of Science ®Google Scholar
• Bergstrom J, Murphy CL, Weiss DT, et al. Two different types of amyloid deposits–apolipoprotein A-IV and transthyretin–in a patient with systemic amyloidosis. Lab Invest. 2004;84(8):981–988.
   PubMed Web of Science ®Google Scholar
• Larsen BT, Mereuta OM, Dasari S, et al. Correlation of histomorphological pattern of cardiac amyloid deposition with amyloid type: a histological and proteomic analysis of 108 cases. Histopathology. 2016;68(5):648–656.
   PubMed Web of Science ®Google Scholar
• Enqvist S, Sletten K, Westermark P. Fibril protein fragmentation pattern in systemic AL-amyloidosis. J Pathol. 2009;219(4):473–480.
   PubMed Web of Science ®Google Scholar
• Engvig JP, Olsen KE, Gislefoss RE, et al. Constant region of a kappa III immunoglobulin light chain as a major AL-amyloid protein. Scand J Immunol. 1998;48(1):92–98.
   PubMed Web of Science ®Google Scholar